FDAnews
www.fdanews.com/articles/84767-advaxis-listeria-cancer-vaccine-gets-regulatory-approval

ADVAXIS' LISTERIA CANCER VACCINE GETS REGULATORY APPROVAL

February 22, 2006

Advaxis has announced that regulators have allowed the company to initiate Phase I/II clinical testing with its lead compound, Listeria-based cancer vaccine, Lovaxin C. Lovaxin C, which specifically targets cervical cancer in women, will be tested for the first time in humans in this study.

Lovaxin C is a therapeutic designed to treat women who have developed cervical cancer as a result of an HPV infection. Preclinical data for Lovaxin C demonstrates an extremely robust immune response to tumors upon administration of the drug and eradication of tumors in more than half of the animals tested.